NCT04337099View on ClinicalTrials.gov

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

Not specified

Conditions
Prostate Cancer
Interventions
DRUG

MBM-02 (Tempol)

Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.

Trial Locations (1)

90292

AVAILABLE

Prostate Oncology Specialists, Marina del Rey

Sponsors
All Listed Sponsors
lead

Matrix Biomed, Inc.

INDUSTRY

NCT04337099 - A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer | Biotech Hunter | Biotech Hunter